Through the analyses of 2,876 patients with MDS from the GenoMed4All consortium, Elisabetta Sauta et al. [37] found that the information on the mutational status of a set of 15 genes (ASXL1, CBL, DNMT3A, ETV6, EZH2, FLT3, IDH2, KMT2A-PTD, NPM1, NRAS, RUNX1, SF3B1, SRSF2, TP53multihit, and U2AF1) could achieve 80% IPSS-M predictive accuracy. This evidence concerns the gene NRAS and myelodysplastic syndrome.